Literature DB >> 12505

Dopamine receptors in human and calf brains, using [3H]apomorphine and an antipsychotic drug.

P Seeman, M Chau-Wong, J Tedesco, K Wong.   

Abstract

In order to develop a better dopamine receptor radioligand, [3H[apomorphine was prepared and tested for dopamine-like binding properties in both calf and human brain tissues. Specific binding of [3H]apomorphine was defined as that binding which occurred in the presence of 1 muM (-)-butaclamol (an inactive neuroleptic) minus that occurring in the presence of 1 muM (+)-butaclamol (active neuroleptic). The specific binding was saturable, the number of sites being double that of specific [3H]dopamine binding, and occurred primarily in dopamine-rich regions of postmortem human brains. The binding had a dissociation constant of 0.9 nM for human caudate (2 nM for calf caudate) and was blocked by dopamine and norepinephrine, but not by isoproterenol or (-)-propranolol, distinguishing it from a beta-adrenergic receptor. Since there was little desorption of [3H]apomorphine, the ligand permits extensive washing during routine assays for dopamine receptors, and facilitates biochemical purification of the receptor.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 12505      PMCID: PMC431452          DOI: 10.1073/pnas.73.12.4354

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

1.  The dopamine receptor: differential binding of d-LSD and related agents to agonist and antagonist states.

Authors:  I Creese; D R Burt; S H Synder
Journal:  Life Sci       Date:  1975-12-01       Impact factor: 5.037

Review 2.  Dopamine receptors in the brain.

Authors:  L L Iversen
Journal:  Science       Date:  1975-06-13       Impact factor: 47.728

3.  Neuroleptic agents of the benzocycloheptapyridoisoquinoline series. 1. Syntheses and stereochemical and structural requirements for activity of butaclamol and related compounds.

Authors:  F T Bruderlein; L G Humber
Journal:  J Med Chem       Date:  1975-02       Impact factor: 7.446

4.  Effect of butaclamol and its enantiomers upon striatal homovanillic acid and adenyl cyclase of olfactory tubercle in rats.

Authors:  W Lippmann; T Pugsley; J Merker
Journal:  Life Sci       Date:  1975-01-15       Impact factor: 5.037

5.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

6.  Dopamine receptor blockade and the neuroleptics, a crystallographic study.

Authors:  A S Horn; M L Post; O Kennard
Journal:  J Pharm Pharmacol       Date:  1975-08       Impact factor: 3.765

7.  The effect of neuroleptics on serum prolactin in schizophrenic patients.

Authors:  H Y Meltzer; V S Fang
Journal:  Arch Gen Psychiatry       Date:  1976-03

8.  The dopamine hypothesis of schizophrenia: focus on the dopamine receptor.

Authors:  S H Snyder
Journal:  Am J Psychiatry       Date:  1976-02       Impact factor: 18.112

9.  Identification of beta-adrenergic receptors in human lymphocytes by (-) (3H) alprenolol binding.

Authors:  L T Williams; R Snyderman; R J Lefkowitz
Journal:  J Clin Invest       Date:  1976-01       Impact factor: 14.808

10.  The behavioral pharmacology of butaclamol hydrochloride (AY-23,028), a new potent neuroleptic drug.

Authors:  K Voith; F Herr
Journal:  Psychopharmacologia       Date:  1975-04-30
View more
  25 in total

1.  Autoradiographic localisation of 3H-apomorphine binding sites in rat brain.

Authors:  M L Bouthenet; N Sales; J C Schwartz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-07       Impact factor: 3.000

Review 2.  Agonist high- and low-affinity states of dopamine D₂ receptors: methods of detection and clinical implications.

Authors:  Jan-Peter van Wieringen; Jan Booij; Vladimir Shalgunov; Philip Elsinga; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-12-09       Impact factor: 3.000

3.  Antiparkinsonian drug doses and neuroleptic receptors.

Authors:  M Titeler; P Seeman
Journal:  Experientia       Date:  1978-11-15

4.  The use of ADTN (2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene) as a ligand for brain dopamine receptors [proceedings].

Authors:  A J Cross; T J Crow; F Owen
Journal:  Br J Pharmacol       Date:  1979-05       Impact factor: 8.739

5.  Dopamine receptors in canine caudate nucleus.

Authors:  H Maeno
Journal:  Mol Cell Biochem       Date:  1982-03-19       Impact factor: 3.396

6.  Genetic regulation of neurotransmitter enzymes and receptors: relationship to the inheritance of psychiatric disorders.

Authors:  R D Ciaranello; R E Boehme
Journal:  Behav Genet       Date:  1982-02       Impact factor: 2.805

7.  Is there a "dopaminergic glial cell"?

Authors:  E Hansson; L Rönnbäck; A Sellström
Journal:  Neurochem Res       Date:  1984-05       Impact factor: 3.996

8.  Dopaminergic binding sites in rat striatal slices and the action of guanyl nucleotides.

Authors:  M P Martres; P Sokoloff; J C Schwartz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-02       Impact factor: 3.000

9.  Interaction of the component enantiomers of the putative dopamine autoreceptor agonist, TL-99 (6,7-dihydroxy-2-dimethylamino tetralin) with dopaminergic systems in mammalian brain and teleost retina.

Authors:  M Williams; G E Martin; D E McClure; J J Baldwin; K J Watling
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-12       Impact factor: 3.000

10.  Dopamine receptor mediated inhibition by pergolide of electrically-evoked 3H-dopamine release from striatal slices of cat and rat: slight effect of ascorbate.

Authors:  J Lehmann; S Arbilla; S Z Langer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-08       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.